Immunological Risk Assessment Transplant Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Immunological Risk Assessment Transplant Market in 2026?

USD 2340.0 million in 2026 and USD 5390.0 million by 2036 at an 8.7% CAGR.

Demand for immunological risk assessment transplant is projected to drive industry valuation from USD 2340.0 million in 2026 to USD 5390.0 million by 2036 at an 8.7% CAGR, supported by more transplant procedures and broader use of molecular surveillance after surgery. The Global Observatory on Donation and Transplantation reported in March 2026 that 173,727 organs were transplanted during 2024. Each completed procedure creates a chain of compatibility checks and follow-up tests.

The United States favors centralized molecular testing and evidence-backed reimbursement. Japan places greater weight on assay specificity because each donor opportunity is difficult to replace. A transplant laboratory must link HLA results with antibody history and graft-injury findings so clinical teams can see whether risk is changing. Comparisons with transplant monitoring kits help executives separate instrument purchases from the repeated assay demand that supports long-term account value.

Summary of the Immunological Risk Assessment Transplant Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Procedure growth expands the number of decisions that require immune-risk evidence across each transplant episode. Transplant programs need donor compatibility results before surgery and graft-injury evidence during follow-up, so one completed procedure can support several distinct laboratory orders over time. During the forecast period, market value is projected to rise at 8.7% CAGR, driven by recurring testing across pre-transplant and post-transplant pathways with different clinical purposes. Molecular surveillance gains commercial relevance when it changes biopsy timing or treatment decisions rather than producing an isolated number without a defined clinical response. Laboratory standardization supports repeat purchasing because clinicians need comparable results across visits and archived findings must remain usable during later risk review.
Product and Segment View	The revenue base is concentrated in routine laboratory consumption rather than one-time equipment purchases. In 2026, Pre-transplant is projected to account for 65.0% share, supported by compatibility work that must be completed before an organ or stem-cell procedure advances. Reagents and Assays are forecast to represent 63.0% share by 2026, attributable to repeat use across donor screening and recipient follow-up episodes. Kidney is estimated to capture 47.0% share during 2026, reinforced by procedure volume and long-term surveillance needs after transplantation. Molecular Assays serve typing and graft-injury questions, although each application requires separate validation and organ-specific clinical interpretation.
Geography and Growth Outlook	Country performance depends on procedure volume and laboratory maturity rather than population size alone. China is estimated to post 11.2% CAGR over the forecast period, aided by tertiary hospital capacity and formal transplant governance across a large provincial system. India is projected to record 10.8% CAGR through 2036, shaped by procedure growth and wider access to accredited testing beyond established metropolitan programs. Japan is forecast to advance at 9.4% CAGR by 2036, underpinned by detailed matching requirements and donor scarcity that raises the value of specificity. The United States combines broad procedure volume with established molecular surveillance and reimbursement pathways for recurring tests.
Competitive Landscape	Competition separates broad immunogenetics portfolios from focused graft-monitoring platforms and laboratory services. Thermo Fisher Scientific and Werfen cover HLA typing plus antibody assessment across transplant laboratories that need integrated compatibility workflows and consistent software-supported interpretation. CareDx and Natera compete through donor-derived cell-free DNA testing and clinical evidence that supports repeated surveillance decisions across kidney and cardiothoracic programs. Eurobio Scientific is extending its transplant laboratory portfolio through GenDx and the CareDx lab-products acquisition across Europe and North America. Verici Dx and Insight Molecular Diagnostics focus on kidney transplant risk and decentralized molecular testing that can fit qualified hospital laboratories with established molecular quality systems.
Analyst Perspective	The commercial question is whether each test changes a clinical decision without adding avoidable complexity to the transplant pathway. High-resolution compatibility testing protects donor selection during pre-surgical review and reduces uncertainty that cannot be corrected following allocation. Post-transplant assays need evidence that links a result with treatment or biopsy action across a defined organ program. Centralized services offer interpretation depth but can add logistics and turnaround dependence, whereas local testing requires enough volume and qualified staff. - Anurag Sharma, Principal Analyst at Future Market Insights

How is the immunological risk assessment transplant market segmented?

The market is assessed by Assessment Stage, Test Type, Technology, Product, Transplant Type, End User, and Region.

The segmentation separates the point of clinical use from the laboratory method and the purchased item. Assessment Stage distinguishes compatibility work from surveillance after transplantation. Test Type separates HLA typing from antibody screening and crossmatch procedures. Technology compares molecular assays with solid-phase immunoassays and cell-based methods. Product analysis divides recurring reagents from instruments plus software and services. Transplant Type shows how procedure mix changes testing demand. End User identifies whether work is completed inside a transplant center or sent to a reference laboratory. The HLA typing category provides a useful benchmark for the core immunogenetics workflow inside this market globally.

What supports demand for Pre-transplant within the Assessment Stage category?

Pre-transplant assessment decides whether a donor-recipient pair can move toward surgery or stem-cell infusion during early clinical planning. NMDP explained in April 2025 that clinicians generally use eight HLA markers to assess donor options that can range from a 4/8 match to an 8/8 match. The result affects donor selection and conditioning plans. reliable DNA RNA extraction is part of the upstream laboratory process because poor sample quality can weaken typing confidence.

• In 2026, Pre-transplant is projected to account for 65.0% share, driven by compatibility testing that must be completed before a transplant proceeds. HLA typing and antibody review are repeated when donor options change or new sensitizing events occur. The segment therefore combines mandatory clinical timing with recurring laboratory demand across organ and stem-cell programs with changing donor lists and repeat crossmatch reviews.
• Transplant immunology laboratories purchase pre-transplant tests to reduce uncertainty around donor selection and antibody risk. the work supports decisions that cannot be deferred until after surgery. Purchase criteria center on resolution and turnaround plus the ability to reconcile current findings with previous samples during urgent donor allocation and later crossmatch review.

How does HLA Typing shape demand within the Test Type category?

HLA typing defines the genetic compatibility information used in donor selection and risk interpretation for complex transplant cases. CareDx announced in October 2025 that AlloSeq Tx11 covers 11 HLA loci within an IVDR-certified next-generation sequencing workflow. Wider locus coverage can reduce ambiguity in complex cases, the related nucleic acid testing category shows why extraction controls and sequence analysis remain part of a complete typing service.

• By test type, HLA Typing is estimated to hold 31.0% share in 2026, attributable to its position at the start of donor matching. Molecular typing supports higher resolution than older serology workflows and creates data that can be reused during antibody interpretation. Laboratories still need software and trained review because a longer sequence output does not remove clinical ambiguity.
• Histocompatibility laboratories favor HLA typing platforms that combine readable workflows with traceable allele calls. the method must fit urgent deceased-donor work and scheduled living-donor cases. Commercial retention depends on technical support because software changes and reference-database updates can affect how results are interpreted during validation and urgent donor-allocation work locally.

How are Molecular Assays positioned within the Technology category?

Molecular assays are used to type immune markers and detect graft-derived signals in blood during patient assessment. Natera reported in May 2025 that a heart-transplant study evaluated 808 Prospera samples from 187 patients with paired biopsies. The study showed how repeated blood testing can be compared with tissue findings. Liquid biopsy workflows are relevant because donor-derived cell-free DNA depends on controlled sampling and analytical interpretation.

• Molecular Assays are forecast to represent 41.0% share in 2026, supported by high-resolution typing and noninvasive graft surveillance. The category covers different clinical questions that should not be treated as commercially interchangeable. a typing assay establishes compatibility, whereas a donor-derived cell-free DNA result measures evidence of graft injury after transplantation.
• Hospital molecular laboratories evaluate assay reproducibility and clinical interpretation alongside instrument fit. a technically accurate result has limited value unless clinicians know what action should follow. Vendors that provide validation support and organ-specific evidence can reduce the internal work needed before routine adoption across separate organ programs and reporting pathways.

What makes Reagents and Assays central to the Product category?

Reagents and assays create repeat revenue each time a patient sample is processed. Eurobio Scientific reported in January 2026 that GenDx generated EUR 33.5 million during 2025 and recorded 9% growth. The result links a focused HLA portfolio with recurring laboratory consumption. Instruments last for several years, whereas typing kits and antibody panels are reordered as cases enter the laboratory.

• In 2026, Reagents and Assays are projected to account for 63.0% share, reinforced by repeated use across donor screening and recipient follow-up. The product mix includes extraction materials and typing kits plus antibody panels and molecular monitoring assays. Demand is therefore tied to case flow rather than the replacement cycle for one analyzer.
• Transplant laboratories select reagents around validated performance and lot consistency plus delivery reliability. a delayed kit can interrupt a time-sensitive compatibility decision. Local inventory and technical support matter because low-volume specialist items may not be stocked through general diagnostic distribution channels with transplant-specific inventory and cold-chain requirements across regions reliably.

How does Kidney shape demand within the Transplant Type category?

Kidney transplantation creates a broad testing pathway that begins with donor matching and continues through rejection surveillance. The Health Resources and Services Administration reported in January 2025 that 27,759 kidney transplants were performed in the United States during 2024. The reported kidney volume supports repeat antibody and molecular testing across a large recipient base. related liver transplantation activity provides a comparison for organ-specific follow-up protocols.

• Kidney is forecast to represent 47.0% share in 2026, owing to procedure volume and the need to protect long-term graft function. Living-donor and deceased-donor programs create different scheduling demands but rely on the same core compatibility evidence. Post-transplant testing adds recurring demand over time after the initial crossmatch has been completed.
• Nephrology and transplant teams use immune-risk tests to distinguish possible rejection from other causes of graft dysfunction. Procurement decisions depend on turnaround and clinical validation plus the ability to fit existing laboratory pathways. Assays gain routine use when results support a clear biopsy or treatment decision during routine outpatient follow-up visits.

How do transplant programs evaluate Transplant Centers within the End User category?

Transplant centers coordinate surgery and immunology data plus longitudinal patient management. CareDx reported in April 2025 that the SHORE registry included more than 2,700 heart-transplant patients across 67 United States centers. Multi-center evidence matters because one laboratory needs results that remain interpretable across different clinical teams. Centralized data review can support consistency across sites but may add sample-shipping dependence and reporting delays.

• Transplant Centers are estimated to capture 57.0% share during 2026, underpinned by their control over donor assessment and post-transplant care. Large programs may operate internal histocompatibility laboratories or maintain formal reference-laboratory relationships. their purchasing decisions often cover assays and software plus education and clinical implementation support across multiple organ programs.
• Hospital transplant committees evaluate whether a testing pathway can be integrated with biopsy review and treatment meetings. a lower price does not offset slow reporting or unclear interpretation. Vendors that understand organ-specific workflows can shorten validation and support broader use across the center during implementation and later method updates without disrupting clinical review.

What are the drivers, restraints, and opportunities in the immunological risk assessment transplant market?

Procedure growth supports recurring testing. donor scarcity constrains completed-case volume. decentralized molecular assays create an opportunity for transplant-center laboratories.

• Driver: Transplant programs are using more molecular evidence to connect a blood result with rejection risk and biopsy planning.
• Restraint: Limited donor supply and uneven specialist laboratory access restrict the number of patients who complete the full testing pathway.
• Opportunity: Kitted molecular assays can move selected graft-surveillance work closer to transplant centers that already operate qualified molecular laboratories.

Market growth is expected to be driven by the expanding clinical evidence behind blood-based graft surveillance across organ programs. CareDx reported in July 2025 that an AlloSure Plus analysis covered more than 4,100 biopsies and improved detection of rejection patterns under the updated Banff framework. The commercial payoff is not the sample count by itself. larger evidence sets give transplant committees a stronger basis for deciding which results can change biopsy timing. The antibody-mediated rejection prevention category is closely linked because early immune injury can alter treatment decisions.

A factor limiting immunological risk assessment transplant adoption is the gap between patients who need organs and the number of transplants completed. NHS Blood and Transplant reported in July 2025 that 8,096 people were active on the United Kingdom waiting list at the end of March 2025. Patients who remain on the list still require some assessment, but they do not create the same post-transplant surveillance pathway as a completed procedure. market expansion therefore depends on donor availability as well as assay adoption inside laboratories.

An emerging opportunity is the transfer of selected molecular monitoring into qualified hospital laboratories with existing sequencing capacity. Insight Molecular Diagnostics reported in September 2025 that its GraftAssureDx trial had expanded from five to 10 transplant centers and enrolled its first patient. a regulated kit could reduce shipping dependence for centers with suitable staff and equipment. The commercial opening is selective rather than universal because local testing requires validation and quality controls plus enough sample volume to justify an internal workflow.

Which country CAGRs are profiled in the immunological risk assessment transplant market?

Country	CAGR
United States	8.8%
Germany	8.1%
United Kingdom	8.4%
France	7.9%
China	11.2%
Japan	9.4%
India	10.8%

How do country-level CAGRs compare in the immunological risk assessment transplant market?

The country comparison spans 4.5 percentage points and shows two closely spaced market groups. China, the United States and South Korea sit within a narrow range that indicates comparable momentum for autonomous line-haul operations. Germany, Canada and Japan form another compact group with moderate differences in projected expansion. The United Kingdom remains close to this second group rather than standing apart from the wider comparison. The overall pattern suggests that market development will differ through route approval and fleet integration rather than demand direction alone.

• China shows notable momentum as large freight networks are expected to support repeated autonomous operations across defined logistics corridors.
• The United States remains close to China while commercial expansion depends on aligning federal safety requirements with separate state road-access rules.
• South Korea occupies a similar position as technology-led fleet programs are anticipated to support hub-to-hub operations across concentrated industrial routes.
• Germany reflects considerable development through motorway testing and route-specific safety cases that connect vehicle approval with terminal readiness.
• Canada remains closely aligned with Germany as long intercity routes support the use case while winter validation shapes operating requirements.
• Japan shows a comparable outlook as labor constraints and expressway-focused freight models encourage relay operations with remote supervision.
• The United Kingdom sits near the second cluster as deployment is expected to progress through defined motorway corridors and approved commercial safety cases.

Markets with similar CAGRs are expected to follow different commercialization paths as road access and remote-support rules vary. These differences influence corridor selection and fleet economics as well as the timing of unattended freight operations. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

• The United States combines high procedure volume with established histocompatibility laboratories and centralized molecular testing services. During the forecast period, the country is projected to grow at 8.8% CAGR, supported by reimbursement experience and broad clinical evidence. United Network for Organ Sharing reported in January 2026 that 49,064 organ transplants were performed during 2025. The volume creates recurring demand for antibody review and graft surveillance after surgery. Large transplant hospitals can compare in-house compatibility workflows with send-out molecular services. Laboratory directors should separate analytical performance from logistics because turnaround and sample transport can change the value of an otherwise accurate result.
• German transplant testing is shaped by accredited laboratories and coordinated organ-allocation procedures. The country is forecast to advance at 8.1% CAGR by 2036, reinforced by standardized laboratory practice and specialist hospital networks. Deutsche Stiftung Organtransplantation reported in January 2026 that 3,256 organs were transplanted in 43 German centers during 2025. The concentration supports reference services and planned reagent purchasing. University hospitals and regional immunogenetics laboratories need products that fit external quality requirements and documented interpretation. Manufacturers that provide German-language support and stable lot performance are better placed to pass local evaluation without adding avoidable validation work or disrupting established reporting procedures.
• Public procurement and national clinical pathways give the United Kingdom a more centralized purchasing structure than the United States. UK demand is estimated to expand at 8.4% CAGR through 2036, attributable to repeat testing within specialist centers and a large waiting list. NHS Blood and Transplant reported in July 2025 that 4,583 patients received a transplant during the 2024/25 year. The procedure base supports compatibility work and follow-up monitoring but budget review remains strict. NHS transplant laboratories need evidence that a new assay improves a defined pathway. Suppliers must show implementation cost and reporting time plus the clinical action supported by each result.
• France operates through a national transplant framework that links allocation oversight with university-hospital care. The immunological risk assessment sector in Franceis projected to record 7.9% CAGR over the forecast period, shaped by standardized transplant activity and specialist laboratory capacity. Agence de la biomédecine reported in February 2026 that France completed 6,148 organ transplants during 2025. Recurring procedures support HLA and antibody testing plus organ-specific surveillance. Hospital groups compare assays through clinical utility and national purchasing constraints. Companies entering France need local scientific support and clear evidence because procurement committees are unlikely to replace an established method for a narrow technical improvement alone.
• China is expanding tertiary medical capacity while revised organ-donation rules increase formal oversight of transplant activity. Adoption is predicted to advance at 11.2% CAGR between 2026 and 2036, aided by hospital investment and wider molecular-laboratory access. The State Council reported in November 2024 that China had more than 38,000 hospitals during 2023. National and provincial centers do not have identical testing capability, which creates a tiered market for imported and domestic assays. Major hospitals in Beijing and Shanghai can support high-resolution workflows. Diagnostics companies need local registration and distributor coverage plus training that reaches provincial laboratory teams across major provinces.
• Japan has a limited deceased-donor pool and detailed living-donor work that places a premium on precise matching. By 2036, demand in Japan is forecast to rise at 9.4% CAGR, underpinned by specificity requirements and long recipient follow-up. Japan Organ Transplant Network recorded 16,679 registered candidates as of July 2025. Scarcity increases the cost of an uncertain donor decision and supports careful antibody interpretation. University hospitals and specialist immunogenetics laboratories favor reliable methods with local documentation. an assay manufacturer can gain trust locally through reproducible performance and direct technical support rather than frequent platform changes that require new validation and staff retraining.
• India has high-volume kidney and liver programs but specialist immunology capacity remains concentrated in metropolitan hospitals. India is estimated to post 10.8% CAGR during the forecast period, driven by procedure growth and wider laboratory investment. National Organ and Tissue Transplant Organization reported in August 2025 that India completed 18,911 organ transplants during 2024. Private hospital groups can adopt molecular tests faster than smaller public centers. Regional reference laboratories can extend access without duplicating specialist equipment in every hospital. Commercial success across India depends on affordable reagents and dependable distribution plus training for complex antibody interpretation outside established transplant hubs.

Who are the notable companies in the immunological risk assessment transplant market?

Thermo Fisher Scientific, Werfen, CareDx, Natera, Eurobio Scientific, Verici Dx, and Insight Molecular Diagnostics are profiled for transplant compatibility or graft-risk testing across pre-transplant and post-transplant workflows.

Competition is divided between broad compatibility platforms and focused post-transplant surveillance. Thermo Fisher Scientific and Werfen supply the laboratory infrastructure used before surgery. CareDx and Natera use centralized testing and clinical evidence to support repeated monitoring. Eurobio Scientific is combining HLA and laboratory products across regions. Verici Dx and Insight Molecular Diagnostics are building narrower kidney-transplant positions. The clinical oncology next-generation sequencing category offers a useful comparison because both markets require validated molecular workflows and careful interpretation rather than instrument performance alone.

• Thermo Fisher Scientific and Werfen compete for laboratory standardization decisions that can remain in place for several years. Their breadth supports typing and antibody workflows, but local service and software integration influence retention after the initial platform choice and during later software or reagent changes.
• CareDx and Natera compete through transplant-specific evidence and recurring testing services across organ programs that require longitudinal risk evidence. Their commercial position depends on clinical adoption and reimbursement plus the ability to explain how a molecular result changes biopsy or treatment decisions across different organ programs and clinical teams.
• Eurobio Scientific is extending GenDx beyond HLA typing through the CareDx laboratory products transaction across Europe and North America. The combined portfolio can offer transplant laboratories more assays through one commercial organization during customer transition. Integration quality remains important for preserving customer continuity and validated laboratory workflows throughout the transfer.
• Verici Dx and Insight Molecular Diagnostics focus on narrower molecular problems within kidney transplant programs that seek local molecular testing options. Their opportunity depends on proving clinical utility and securing regulatory or laboratory adoption without requiring centers to rebuild established compatibility workflows or imposing an unsupported interpretation burden on clinicians.

Competitive Benchmarking: Immunological Risk Assessment Transplant Market

Company	Pre-transplant HLA	Antibody Testing	Molecular Monitoring	Clinical Evidence	Geographic Reach
Thermo Fisher Scientific	High	High	Medium	High	North America, Europe, Asia, and other regions
Werfen	High	High	Low	High	North America, Europe, Asia, and selected regions
CareDx	Medium	Medium	High	High	United States and selected international programs
Natera	Low	Low	High	High	United States with international evidence activity
Eurobio Scientific	High	High	Medium	Medium	Europe, North America, and distributor markets
Verici Dx	Low	Low	Medium	Medium	United States and United Kingdom base
Insight Molecular Diagnostics	Low	Low	Medium	Medium	United States with early international sites

Key Developments in the Immunological Risk Assessment Transplant Market

• In March 2025, CareDx expanded AlloSure Heart testing to pediatric heart recipients younger than 15 and expanded AlloSure Kidney to simultaneous pancreas-kidney recipients. the action broadened the clinical populations covered by the company’s donor-derived cell-free DNA services. It matters commercially because a validated indication can convert exception-based testing into a repeatable surveillance pathway for a defined transplant group across routine pediatric and combined-organ follow-up.
• In April 2025, Natera reported results from the DEFINE-HT study after more than 1,100 donor-derived cell-free DNA tests in heart recipients. The company stated that elevated Prospera results correlated with adverse outcomes and performed better than biopsy findings for later graft dysfunction in the study. The development strengthens the evidence base needed for transplant committees to decide how blood testing fits routine surveillance.
• In May 2026, Werfen entered a strategic collaboration with Oxford Nanopore to validate HLA typing and pre-transplant matching assays on nanopore sequencing platforms. the work targets faster sample-to-result workflows and lower implementation complexity for transplant laboratories. Commercial adoption still depends on local validation, but the collaboration could extend high-resolution typing to laboratories that need flexible sequencing capacity without replacing the existing clinical review process.

Key Players in the Immunological Risk Assessment Transplant Market

Broad Transplant Laboratory Platforms

• Thermo Fisher Scientific
• Werfen
• Eurobio Scientific

Molecular Surveillance Specialists

• CareDx
• Natera

Focused Kidney Transplant Diagnostics

• Verici Dx
• Insight Molecular Diagnostics

Immunological Risk Assessment Transplant Market - Report Scope

Coverage field	Report scope
Market breakdown	Assessment Stage, Test Type, Technology, Product, Transplant Type, End User, and Region.
Market Definition	Immunological risk assessment transplant products and services evaluate donor-recipient compatibility during pre-transplant assessment or post-transplant surveillance. The scope includes HLA typing, antibody testing, crossmatch methods, and molecular graft surveillance.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East and Africa.
Countries Covered	United States, Germany, United Kingdom, France, China, Japan, India, and 30+ countries within the regional model.
Key Companies Profiled	Thermo Fisher Scientific, Werfen, CareDx, Natera, Eurobio Scientific, Verici Dx, and Insight Molecular Diagnostics.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Immunological Risk Assessment Transplant Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Immunological Risk Assessment Transplant Market by Segments

Immunological Risk Assessment Transplant Market segmented by Assessment Stage:

• Pre-transplant
• Post-transplant

Immunological Risk Assessment Transplant Market segmented by Test Type:

• HLA Typing
• Antibody Screening
• Crossmatch Testing
• Immune Monitoring
• Molecular Injury Testing

Immunological Risk Assessment Transplant Market segmented by Technology:

• Molecular Assays
• Solid-Phase Immunoassays
• Flow Cytometry
• Cell-Based Assays

Immunological Risk Assessment Transplant Market segmented by Product:

• Reagents and Assays
• Instruments
• Software and Services

Immunological Risk Assessment Transplant Market segmented by Transplant Type:

• Kidney
• Liver
• Heart
• Lung
• Stem Cell
• Other Organs

Immunological Risk Assessment Transplant Market segmented by End User:

• Transplant Centers
• Reference Laboratories
• Blood Banks
• Research Institutes

Immunological Risk Assessment Transplant Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Mexico
  • Brazil
  • Chile
  • Rest of Latin America
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Nordic Countries
  • Benelux
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Oceania
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Oceania
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East and Africa

Research Sources and Bibliography

• 1. Global Observatory on Donation and Transplantation. (2026, March). Organ donation and transplantation worldwide. World Health Organization and Organización Nacional de Trasplantes.
• 2. CareDx. (2026, February 24). CareDx announces fourth quarter and full year 2025 financial results. CareDx Investor Relations.
• 3. NMDP. (2025, April 10). Donor options and making treatment decisions. NMDP.
• 4. CareDx. (2025, October 6). CareDx announces new IVD products and IVDR certification for AlloSeq Tx and QTYPE. CareDx Investor Relations.
• 5. Natera. (2025, May 7). Prospera Heart test with DQS outperforms dd-cfDNA percentage in detecting allograft rejection. Natera.
• 6. Eurobio Scientific. (2026, January 27). FY 2025 revenue. Eurobio Scientific.
• 7. Health Resources and Services Administration. (2025, January 15). Organ transplants exceeded 48,000 in 2024. USA Department of Health and Human Services.
• 8. CareDx. (2025, April 24). CareDx announces presentation of 60 abstracts including 19 oral presentations at the 2025 ISHLT meeting. CareDx Investor Relations.
• 9. CareDx. (2025, July 31). CareDx announces transplant diagnostics data at the 2025 World Transplant Congress. CareDx Investor Relations.
• 10. NHS Blood and Transplant. (2025, July 9). Organ transplant waiting list hits record high as donor and transplant numbers fall. NHS Blood and Transplant.
• 11. Insight Molecular Diagnostics. (2025, September 8). IMDX enrolls first patient in GraftAssureDx clinical trial and welcomes new hospital participants. Insight Molecular Diagnostics Investor Relations.
• 12. United Network for Organ Sharing. (2026, January 28). United States surpasses 49,000 organ transplants while deceased organ donations dip. United Network for Organ Sharing.
• 13. Deutsche Stiftung Organtransplantation. (2026, January 13). Organspende und Transplantation in Deutschland 2025. Deutsche Stiftung Organtransplantation.
• 14. Agence de la biomédecine. (2026, February 19). 6,148 organ transplants in 2025: an all-time record for France. Agence de la biomédecine.
• 15. State Council of the People’s Republic of China. (2024, November 30). China announces pilot plan for wider opening in the medical sector. The State Council of the People’s Republic of China.
• 16. Japan Organ Transplant Network. (2025, July 31). News Letter No. 29. Japan Organ Transplant Network.
• 17. National Organ and Tissue Transplant Organization. (2025, August). Annual report 2024-25. Ministry of Health and Family Welfare, Government of India.
• 18. CareDx. (2025, March 6). CareDx launches two expanded indications for AlloSure testing services. CareDx Investor Relations.
• 19. Natera. (2025, April 29). Prospective DEFINE-HT study demonstrates that Prospera Heart predicts clinical outcomes. Natera.
• 20. Werfen. (2026, May 14). Werfen and Oxford Nanopore enter strategic collaboration to support development of advanced transplant assays. Werfen.
• 21. Eurobio Scientific. (2026, April 16). Eurobio Scientific signs definitive agreement to acquire CareDx transplant lab product division. Eurobio Scientific.
• 22. Eurobio Scientific. (2026, July 1). Eurobio Scientific finalizes the acquisition of CareDx transplant lab product division. Eurobio Scientific.
• 23. Thermo Fisher Scientific. (n.d.). Transplant diagnostics products and solutions. Thermo Fisher Scientific.
• 24. Werfen. (n.d.). Transplant diagnostics assays for typing and antibody testing. Werfen.
• 25. CareDx. (n.d.). Transplant solutions. CareDx.
• 26. Natera. (n.d.). Prospera transplant assessment. Natera.
• 27. Eurobio Scientific. (n.d.). Transplantation diagnostics. Eurobio Scientific.
• 28. Verici Dx. (2026, June). Annual report and accounts for the year ended 31 December 2025. Verici Dx.
• 29. Insight Molecular Diagnostics. (2026, March 26). IMDX submits GraftAssureDx for FDA review and reports Q4 2025 results. Insight Molecular Diagnostics Investor Relations.

All sources are primary non-commercial government, regulatory, academic, trade body, or official company publications.

This Report Answers

• How does the market move from USD 2,340.0 million in 2026 to USD 5,390.0 million by 2036?
• Which clinical and laboratory factors support the 8.7% CAGR forecast from 2026 to 2036?
• Why does Pre-transplant account for 65.0% share within the Assessment Stage category during 2026?
• How do HLA typing and antibody screening differ from molecular graft-injury surveillance in purchasing and clinical use?
• Which transplant types create the most recurring demand for compatibility assessment and post-transplant immune-risk testing?
• How do public procurement and reimbursement pathways change adoption across the United States and European transplant systems?
• Why do China and India record higher country CAGRs than Germany and France during the forecast period?
• Which companies compete through broad laboratory platforms and which focus on molecular transplant surveillance services?
• What operational limits can reduce the return on investment from decentralized molecular testing inside transplant centers?
• How were procedure data and company activity plus segment structure reconciled within the market forecast?